Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

The Trump administration has cut around 100 employees, or roughly 10%, of the federal agency that oversees mental and ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

የሚሊዮን ዜጎችን ህይወት የቀጠፈው ኤችአይቪ ኤድስ በሽታ እስካሁን ፈዋሽ መድሃኒት ያልተገኘለት ሲሆን የዓለም ጤና ድርጅት ለቫይረሱ መድሃኒት ለማግኘት የተለያዩ ጥረቶችን በማድረግ ላይ ነው፡፡ ከአምስት ዓመት በኋላ ማለትም በ2030 የቫይረሱን ወረርሽኝ የማጥፋት እቅድ ያስቀመጠ ሲሆን ለዚህ የሚረዱ የተለያዩ ሙከራዎች ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

New breakthrough drugs and research could help to end major global epidemics such as malaria and HIV. But U.S. funding cuts ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

An annual injection to prevent HIV infection is closer to becoming reality after the first stage of a drug trial showed promising results.

A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...